Bausch Health Companies Inc.
$22.14B- Market cap
- $2.40B
- Debt
- +$21.04B
- Cash
- −$1.31B
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.14x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BHC stock price vs ASTS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ASTS's multiple
Needs ASTS P/E.
Implied fair value · at BHC's multiple
Needs Annual EPS is negative.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · ASTS FY 2025 (ended Dec 31, 2025).
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.14x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
AST SPACEMOBILE, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-37.98x
0.93x
Net debt / EBITDA
Leverage against operating earnings
8.15x
6.49x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$4.34B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
Iridium Communications Inc.
BHC vs IRDM
VIASAT INC
BHC vs VSAT
Globalstar, Inc.
BHC vs GSAT
Rocket Lab USA, Inc.
BHC vs RKLB
$21.04B
$2.22B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.